Open-Label vs Blinded Designs in BA/BE Studies: Strategic and Regulatory Implications
Open-Label vs Blinded Designs in BA/BE Studies: Strategic and Regulatory Implications Open-Label or Blinded? Choosing the Right Design for BA/BE Trials Introduction: The Role of Masking in Bioequivalence Trials In clinical research, the terms open-label and blinded describe whether trial participants, investigators, or assessors know which treatment is being administered. In bioavailability and bioequivalence (BA/BE)…
Read More “Open-Label vs Blinded Designs in BA/BE Studies: Strategic and Regulatory Implications” »